1-(5'-O-methyl-β-D-arabinofuranosyl)cytosine | 35819-08-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-(5'-O-methyl-β-D-arabinofuranosyl)cytosine
• 英文别名: 5'-O-methyl-β-D-arabinosylcytosine；1-(5-O-Methyl-β-D-arabinofuranosyl)cytosin；5'-Methyl-1-β-D-arabinofuranosylcytosin；4-amino-1-(O⁵-methyl-β-D-arabinofuranosyl)-1H-pyrimidin-2-one；2(1H)-Pyrimidinone, 4-amino-1-(5-O-methyl-beta-D-arabinofuranosyl)-；4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(methoxymethyl)oxolan-2-yl]pyrimidin-2-one
• CAS: 35819-08-0
• 化学式: C₁₀H₁₅N₃O₅
• 分子量: 257.246
• InChiKey: AQZIBVNEPZLCGR-BUJSFMDZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(5'-O-methyl-β-D-arabinofuranosyl)cytosine 在 sodium hydroxide 作用下， 生成 1-(5'-O-methyl-β-D-arabinofuranosyl)uracil
  参考文献：
  名称：

  Lönnberg; Suokas; Käppi, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1986, vol. 40, # 10, p. 798 - 805

  摘要：

  DOI：

文献信息

• PROTECTED NUCLEOTIDE ANALOGS
  申请人：Beigelman Leonid

  公开号：US20100240604A1

  公开（公告）日：2010-09-23

  Disclosed herein are nucleotide analogs with protected phosphates, methods of synthesizing nucleotide analogs with protected phosphates and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with protected phosphates.

  本文披露了具有保护磷酸酯基团的核苷酸类似物，以及合成具有保护磷酸酯基团的核苷酸类似物的方法，以及利用具有保护磷酸酯基团的核苷酸类似物治疗病毒感染、癌症和/或寄生虫病等疾病和/或症状的方法。
• Antiviral nucleosides
  申请人：Sarma Keshab

  公开号：US20070232562A1

  公开（公告）日：2007-10-04

  Compounds having the formula I wherein R 1 is as herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, processes for making the compounds and synthetic intermediates used in the process

  具有公式I的化合物，其中R1如本文所定义，是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于抑制肝炎复制的组合物和方法，制备化合物的工艺以及工艺中使用的合成中间体。
• DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION
  申请人：IDENIX PHARMACEUTICALS, INC.

  公开号：US20140112886A1

  公开（公告）日：2014-04-24

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds comprise two 2′-methyl nucleotides linked according to Formula I: N 1 -L-N 2 (I) or a pharmaceutically acceptable salt, ester, solvate, stereoisomer, isomeric form, tautomeric form or polymorphic form thereof; wherein N 1 , L and N 2 are as described herein.

  本文提供了用于治疗黄病毒科感染，包括HCV感染的化合物、组合物和方法。在某些实施方式中，披露了核苷类衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合给药。在某些实施方式中，所述化合物包括根据以下式I连接的两个2'-甲基核苷酸：N1-L-N2(I)或其药学上可接受的盐、酯、溶剂合物、立体异构体、同分异构体、互变异构体或其多形形式；其中N1、L和N2如本文所述。
• NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20150315221A1

  公开（公告）日：2015-11-05

  The present invention relates to disulfide masked prodrug compounds, compositions and methods that are amenable to bioactivation by a reducing agent such as glutathione. Such disulfide based compounds, compositions, and methods can be useful, for example, in providing novel prodrugs for use as therapeutics.

  本发明涉及一种二硫化物掩蔽的前药化合物、组合物和方法，这些化合物、组合物和方法可通过还原剂如谷胱甘肽进行生物活化。这种基于二硫化物的化合物、组合物和方法可以用于提供新型前药，例如用作治疗药物。
• Sugar modified nucleosides as viral replication inhibitors
  申请人：Hong Zhi

  公开号：US20070032448A1

  公开（公告）日：2007-02-08

  Various 2′-modified nucleoside analogs and corresponding prodrugs are provided, and particularly contemplated methods of use include use as antiviral agents, and especially as antiviral agents against HCV.

  提供了各种2'-修饰核苷类似物及相应的前药，特别考虑使用的方法包括用作抗病毒剂，尤其是用作抗HCV的抗病毒剂。